Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease

The FDA have recently published draft guidance for the development of treatments for early Alzheimer’s disease. Key features of this guidance are the advocacy of sensitive cognitive measures and a taxonomy of …